Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 13, 2018 07:00 ET | Source: BeiGene, LTD.

BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., and BEIJING, China, Nov. 13, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
November 07, 2018 07:00 ET | Source: BeiGene, LTD.

BeiGene Initiates Global Head-to-Head Phase 3 Clinical Trial of Zanubrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

CAMBRIDGE, Mass. and BEIJING, China, Nov. 07, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
November 07, 2018 07:00 ET | Source: BeiGene, LTD.

BeiGene Reports Third Quarter 2018 Financial Results

CAMBRIDGE, Mass. and BEIJING, China, Nov. 07, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
November 05, 2018 07:00 ET | Source: BeiGene, LTD.

BeiGene to Present Clinical Data on PARP Inhibitor Pamiparib at Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology

CAMBRIDGE, Mass. and BEIJING, China, Nov. 05, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
November 01, 2018 09:00 ET | Source: BeiGene, LTD.

BeiGene to Present Clinical Data on Tislelizumab and Zanubrutinib at the 60th American Society of Hematology Annual Meeting

Company to Host Investor Meeting and Webcast on Monday, December 3, at 8 pm PST CAMBRIDGE, Mass. and BEIJING, China, Nov. 01, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE), a...
October 24, 2018 07:00 ET | Source: BeiGene, LTD.

BeiGene Announces Acceptance of its New Drug Application in China and Top-Line Pivotal Data for Zanubrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

BEIJING, China, and CAMBRIDGE, Mass., Oct. 24, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
October 22, 2018 07:15 ET | Source: BeiGene, LTD.

BeiGene Presents Preliminary Clinical Data on PARP Inhibitor Pamiparib in Combination with Low-Dose Temozolomide in Patients with Solid Tumors at European Society for Medical Oncology (ESMO) 2018 Congress

CAMBRIDGE, Mass. and BEIJING, China, Oct. 22, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
October 12, 2018 06:00 ET | Source: BeiGene, LTD.

BeiGene Announces Updated Results from Phase 1 Clinical Trial of Zanubrutinib in Patients with Waldenström’s Macroglobulinemia

CAMBRIDGE, Mass. and BEIJING, China, Oct. 12, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
October 10, 2018 06:00 ET | Source: BeiGene, LTD.

BeiGene Announces National Reimbursement Inclusion of VIDAZA® (Azacitidine for Injection) by the State Medical Insurance Administration in China

BEIJING, China and CAMBRIDGE, Mass., Oct. 10, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
October 08, 2018 18:05 ET | Source: BeiGene, LTD.

BeiGene to Present Clinical Data on Zanubrutinib and Pamiparib at Upcoming Medical Meetings

CAMBRIDGE, Mass. and BEIJING, China, Oct. 08, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...